Table 2.
Metabolic characteristics of the LETO control and control or ezetimibe-treated OLETF
| LETO control (n = 3) | OLETF control (n = 5) | OLETF Ezetimibe (n = 6) | |
| Body weight (g) | 524.00 ± 1.15b | 617.67 ± 23.29 | 642.29 ± 20.47 |
| Daily food intake (g) | 3.61 ± 0.12b | 5.06 ± 0.30 | 4.62 ± 0.13 |
| Liver tissue weight (%BW) | 2.52 ± 0.05a | 3.60 ± 0.29 | 2.90 ± 0.10a |
| Serum concentration | |||
| Glucose (mmol/L) | 5.24 ± 0.01b | 10.23 ± 0.13 | 7.25 ± 0.08b |
| Insulin (ng/mL) | 0.10 ± 0.002b | 0.82 ± 0.08 | 0.29 ± 0.05b |
| HOMA-IR | 0.57 ± 0.01b | 3.84 ± 0.26 | 1.75 ± 0.04b |
| TG (mmol/L) | 4.56 ± 0.08b | 12.94 ± 0.94 | 9.83 ± 0.94a |
| FFA (mmol/L) | 0.37 ± 0.01b | 0.69 ± 0.02 | 0.51 ± 0.02b |
| TC (μmol/L) | 124.02 ± 4.34b | 466.22 ± 12.32 | 255.08 ± 5.10b |
| Liver concentration | |||
| TG (mmol/mg protein) | 14.75 ± 0.72b | 22.72 ± 1.21 | 6.66 ± 1.01b |
| FFA (nmol/mg protein) | 9.93 ± 0.64b | 18.90 ± 1.35 | 13.10 ± 0.60b |
| TC (nmol/mg protein) | 4.74 ± 0.41b | 17.81 ± 0.98 | 12.66 ± 0.50b |
Data are expressed as the mean ± SE.
a
P < 0.05,
b
P < 0.01 vs OLETF control. BW: Body weight; FFA: Free fatty acids; HOMA-IR: Homeostasis model assessment of insulin resistance; TC: Total cholesterol; TG: Triglycerides.